Related Experiment Video

Updated: May 30, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Statins in non-ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding

N Verma1, V M Figueredo

  • 1Institute for Heart & Vascular Health, Albert Einstein Medical Center, PA 19141, USA.

International Journal of Clinical Practice
|August 20, 2011
PubMed

Insights

Statins offer cardiovascular benefits beyond cholesterol reduction, potentially improving outcomes in heart failure (HF) patients. This review explores statins' pleiotropic effects in non-ischaemic heart failure, suggesting novel therapeutic mechanisms.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins are primary agents for cardiovascular event reduction.
  • Evidence suggests statin benefits extend beyond lipid-lowering, implying pleiotropic effects.
  • Observational studies link statins to improved outcomes in heart failure (HF) patients, regardless of aetiology.

Purpose of the Study:

  • To review the evidence for statin therapy in heart failure.
  • To explore the potential pleiotropic mechanisms of statins in non-ischaemic heart failure.

Main Methods:

  • Literature review of observational, non-randomised, and retrospective studies on statin use in heart failure.
  • Analysis of proposed mechanisms of action for statins in cardiovascular disease.

Main Results:

  • Statins demonstrate benefits in cardiovascular event reduction, even in individuals with normal or low cholesterol.
  • Statins are associated with better outcomes in both ischaemic and non-ischaemic heart failure.
  • While cholesterol reduction and plaque stabilization explain benefits in ischaemic HF, mechanisms in non-ischaemic HF are less understood.

Conclusions:

  • Statins possess pleiotropic effects that may be crucial for their therapeutic benefits in heart failure.
  • These pleiotropic mechanisms could beneficially modulate pathophysiological processes in non-ischaemic heart failure.
  • Further research into statins' non-lipid-lowering effects is warranted for optimizing heart failure treatment.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...